The aim of our study was to evaluate whether serum asymmetric dimethylarginine (ADMA) level is an independent predictor of contrast-induced nephropathy (CIN).
C ontrast-induced n e p h r o p a t h y (CIN) is a serious complication of iodinated contrast media exposure. Regardless of the patients' baseline characteristics, such as creatinine clearance (CrCl), left ventricular ejection fraction (LVEF), coronary artery disease, diabetes mellitus (DM), and hemodynamic status, the development of CIN correlates with increased in-hospital morbidity and mortality rates attributable to CIN. [1] Not only the patients with CIN requiring dialyses but also those developing mild renal impairment have poor outcomes. [1] In addition, CIN worsens long-term prognosis and is associated with late cardiovascular events. [2] Because the pathogenesis of CIN is dependent on a complex interplay of multiple factors and this syndrome is an independent predictor of potential adverse outcomes, numerous studies have focused their investigations on the risk stratification for CIN. Both patient-and procedure-related characteristics were evaluated in these studies to most accurately identify the population at risk for CIN. [1, 3] The pathophysiology of CIN is still poorly understood; however, it is clear that the patients with higher atherosclerotic burden and endothelial dysfunction are more vulnerable to contrast agents. [4, 5] Previous studies have demonstrated that the patients with hypertension, DM, hypercholesterolemia, acute coronary syndrome, advanced age, multivessel disease, and peripheral vascular disease had higher risk for the development of CIN. [3, [6] [7] [8] Asymmetric dimethyl-l-arginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, is a surrogate marker of endothelial dysfunction. [9, 10] In many studies, ADMA levels were found to be elevated in various conditions associated with atherosclerosis and endothelial dysfunction. [9] [10] [11] Further, elevated ADMA levels have been demonstrated to be associated with increased oxidative stress and impaired NO production, some of the proposed mechanisms for the development of CIN. [9, 12] To our knowledge, no study in the literature thus far has investigated the presence or not of a relation between CIN and serum ADMA levels. The aim of our study was to evaluate whether or not serum ADMA level could be used as an independent marker in the prediction of CIN.
PATIENTS AND METHODS

Study population
The study involved 90 consecutive patients with stable angina pectoris who underwent coronary angiography and ventriculography. Baseline serum creatinine (SCr) levels of all subjects ranged between ≥1.2 and <2 mg/dl. Exclusion criteria included current infection, neoplasm, acute coronary syndromes, contraindications to iodinated contrast agents (e.g., history of allergic reactions against contrast media), need for urgent percutaneous coronary intervention, and recent exposure to contrast media or nephrotoxic agent (within 7 days before the study). Any patients requiring theophylline/aminophylline or dopamine throughout the study were also excluded. Each subject was questioned about the confirmed risk factors for atherosclerotic heart disease and CIN including hypertension, hyperlipidemia, DM, smoking status, and medications.
Study design
All patients were hydrated with intravenous isotonic saline at a rate of 1 ml/kg per hour for 6 hours before and 12 hours after the procedure. Before coronary procedures, echocardiographic examination was carried out in all patients by a cardiology specialist using Vingmed System 7 echocardiography machine and a 2.5 MHz probe. LVEF was measured by two-dimensional echocardiography via the modified Simpson method. Left and right coronary angiography was performed in multiple projections by the Judkins or Sones technique via the right femoral artery using Philips Integris 5000 equipment (Philips Medical Systems, Best, The Netherlands). Iopromide, a low-osmolar, nonionic contrast agent, was used in all procedures. SCr concentration was measured in venous blood at baseline (before initiating preprocedure hydration) and on day 2 after the procedure. The primary end point was the occurrence of CIN. We defined CIN as an increase ≥0.5 mg/ dl and/or ≥25% in SCr concentration at day 2 of the procedure. The secondary end point was the change in SCr levels at day 2 after the contrast exposure.
Creatinine clearance was estimated by the Cockcroft-Gault formula. [13] We also estimated Mehran risk score [3] in all patients. Mehran risk score was de- , and <20 ml/ min/1.73 m 2 , respectively), anemia (3 points), congestive heart failure (5 points), DM (3 points), hypotension (5 points), and age >75 years (4 points). The procedure-related variables included the need for an intraaortic balloon pump within 24 hours periprocedurally (5 points) and contrast media volume (1 point for each 100 cc 3 ).
The study was approved by the local ethics committee, and a written informed consent was obtained from all patients enrolled in the study.
ADMA
Serum samples for the measurement of ADMA level were drawn between 800-1000 hours and were preserved at -70°C. Serum ADMA was determined using enzyme-linked immunosorbent assay (ELISA) kit (Eastbiopharm, Hangzhou) based on the principle of double-antibody sandwich technique.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS) for Windows version 15.0 software (Chicago, IL, USA) was used as the statistical software program. Kolmogorov-Smirnov test was used to determine whether the parameters fit with the normal distribution. Data within the normal distribution were expressed as mean±standard deviation (Mean±SD). Results of data without normal distribution are shown by median (interquartile range) expression. MannWhitney U-test was used to compare data that did not fit with the normal distribution between two groups. Unpaired Student t-test was used for comparing data within the normal distribution between two groups. Chi-square test was used for comparison of categorical variables. We performed multivariate logistic regression analyses to determine independent associations between the potential risk markers and CIN. The receiver operating characteristic (ROC) curve was used to determine the sensitivity and specificity of serum ADMA level and the optimal cut-off value for predicting CIN. The association between change in SCr levels and ADMA values was evaluated by calculating the Spearman's correlation coefficient. A p value under 0.05 was accepted as the level of significance.
RESULTS
Our study population comprised 90 consecutive patients with stable angina pectoris who underwent coronary angiography and ventriculography. CIN occurred in 10 patients according to our CIN definition. CIN rate was 11.1%. Mehran risk score of the entire population was 6 (5-8). Table 1 shows baseline demographic, clinical characteristics and medications in both the CIN(-) (80 patients) and CIN (+) (10 patients) groups. There was no significant difference between the CIN(+) and CIN(-) groups with regard to age, sex, hypertension, smoking, body mass index (BMI), LVEF, baseline Cr, baseline CrCl, contrast agent dose, lipid profile, hemoglobin, and medications (Table 1) .
However, we detected a statistically significantly higher serum ADMA level in the CIN(+) group compared to that of the CIN(-) group (210.6 ng/ml (115.6-217.2) vs. 91.5 ng/ml (65.2-122.1), p=0.01) ( Table  1 , Fig. 1 { ment of CIN. In addition, we found a statistically significant correlation between the levels of SCr change and serum ADMA levels, but this correlation was low to moderate (p=0.001, r=0.35) (Fig. 3) .
The ROC curves of serum ADMA level for predicting CIN are shown in Figure 2 . In this study, a serum ADMA level of >124.7 ng/ml had 80% sensitivity and 76% specificity in predicting the develop- 
DISCUSSION
Contrast-induced nephropathy is the third most common cause of hospital-acquired renal failure. [14] Because of the high mortality and morbidity rates attributed to CIN, many studies have been designed to disclose how clinicians can best predict the patients at risk for CIN. More accurate prediction of CIN facilitates taking preventive measures earlier and monitoring renal function tests more closely. To date, many individual risk factors have been reported and several risk prediction models have been developed based on these factors. [1, 3, 14] Advanced age, basal renal dysfunction, DM, anemia, hypertension, hemodynamic instability, high contrast volume, and heart failure are well-known risk factors for CIN. These risk factors have been proven by many studies and have been included in risk-scoring schemes. [1, 3, [6] [7] [8] 14] In addition, many studies have shown that the risk for CIN was higher in patients with more severe and extensive cardiovascular disease. [1, 7, 8, 15] In other words, CIN was more likely to occur in patients with more extensive atherosclerotic burden and endothelial dysfunction.
Although little is known about the underlying cellular mechanisms in the pathophysiology of CIN, decrease in NO production and increase in oxidative stress have been suggested in many studies as some of the underlying mechanisms leading to vasoconstriction, direct renal tubular damage and CIN. [16] [17] [18] Thus, in the literature, many agents have been studied for their potential to prevent the negative effects of radiocontrast on renal function based on these mechanisms. For instance, N-acetylcysteine (NAC), the most commonly used agent for CIN prophylaxis, has been evaluated by numerous studies due to its antioxidative properties. [19, 20] In addition, the value of statins in the prevention of CIN has been evaluated by many authors, since statins increase NO bioavailability, improve endothelial function and have antioxidative properties. [21, 22] It should be highlighted that many promising results have been achieved with those agents that exert antioxidative and anti-inflammatory effects, increase NO bioavailability and improve endothelial function. [20, 21, 23] It is well known that secretion of NO is one of the main functions of the endothelium. NO, a potent vasodilator, is synthesized by NOS, and its synthesis reduces in the presence of endothelial dysfunction. [24] ADMA, an endogenous competitive inhibitor of NOS, impairs endothelial function, thus leading to atherosclerosis and atherosclerosis-related diseases. [25] [26] [27] Increased plasma ADMA levels have been shown in patients with coronary artery disease, [26] peripheral arterial disease, [28] DM, [29] hypertension, [30] stroke, [31] hyperhomocysteinemia, [32] and end-stage renal disease, [33] all of which have already been proven to be related to endothelial dysfunction. Furthermore, several studies have reported that ADMA induces oxidative stress. [12, 34] In this context, the study conducted by Mihout et al. [35] is especially noteworthy because they demonstrated clearly increased renal oxidative stress in rats exposed to exogenous ADMA. They showed elevated superoxide anion (O2-) levels in ADMA-administered rats. Besides increasing endothelial dysfunction and oxidative stress, ADMA could be involved in the progression of renal injury. In a study reported by Fliser et al., [36] ADMA was found to predict the progression of chronic kidney disease. In that study, the renal functions of the patients with higher ADMA levels deteriorated faster than those with lower ADMA. Likewise, Lajer et al. [37] demonstrated that elevated ADMA levels predicted the deterioration of glomerular filtration rate during an 11.3-year follow-up period in type 1 diabetic patients. The effect of ADMA on renal injury can be summarized as induction of glomerular fibrosis, increased renal concentration of TGF-a1 and collagen type 1, as well as increased renal oxidative stress. [35] Accurate risk stratification for CIN is extremely important to determine the evidence-based prophylactic measures. To date, for prediction of CIN, many risk scoring schemes have been published. However, no scheme used any marker for this purpose. Based on the above-mentioned data about the pathogenesis of CIN and the effect of ADMA on endothelial function, oxidative status and renal damage, we aimed to understand whether ADMA could be used as a marker in the prediction of CIN. The main result of our study is that ADMA is an independent risk marker for the development of CIN. This study is unique because no study to date has demonstrated any relationship between serum ADMA level and CIN. It is noteworthy that only a few studies have evaluated biomarkers in CIN prediction. Osthoff et al. [38] showed that mannosebinding lectin is an inverse predictor of CIN. Another study conducted by McCullough et al. [39] demonstrated that baseline neutrophil gelatinase-associated lipocalin (NGAL) is an independent predictor of changes in the post-contrast NGAL. Although many risk prediction schemes for CIN are available, clinicians lack risk prediction biomarkers. We believe that in order to indentify high-risk patients earlier and more accurately, new studies that will bring novel biomarkers into clinical practice are necessary. In our study, we found higher serum ADMA level in the CIN(+) group compared to that of the CIN(-) group. We also demonstrated that a serum ADMA level of >124.7 ng/ml had 80% sensitivity and 76% specificity in predicting the development of CIN. Despite the small patient population of our study, we suggest that ADMA deserves further examination as a potential marker in the prediction of CIN. The Mehran risk-scoring method is the most frequently used scheme in CIN prediction. It is important to note that the CIN ratio (11%) of the present study was concordant with the study of Mehran et al., suggesting a CIN risk of 7.5% and 14% for risk scores of 1-6 and 6-10, respectively. Furthermore, in our study, DM was found to be an independent risk factor for CIN as well as the Mehran risk score, as suggested in previous studies. [1, 3, 5] 
Study limitations
The major limitation of the present study is the enrollment of a limited number of patients. Larger studies are necessary to confirm our findings. In addition, Mehran risk scores of most patients in our study were below 10. Therefore, our study did not reveal the value of ADMA in CIN prediction in high-risk patients. In addition, we defined CIN as an increase ≥0.5 mg/ dl and/or ≥25% in SCr concentration at day 2 of the procedure. However, SCr level may increase up to 1-2 weeks after contrast exposure. [1, 23] Therefore, some patients with CIN may be overlooked. Lastly, ADMA concentrations were assessed by ELISA method in our study. However, high-performance liquid chromatography (HPLC) assay is suggested as a robust method to measure ADMA level with high accuracy.
In conclusion, our study demonstrates that serum ADMA level is an independent predictor for the development of CIN. Large, prospective, multicenter studies will be required to understand more clearly the future role of ADMA as a risk prediction marker of CIN.
Conflict-of-interest issues regarding the authorship or article: None declared
